NASD · Healthcare · Drug Manufacturers - General · Ireland
Amarin Corp ADR is a micro cap company (market value under $300 million) in the Drug Manufacturers - General industry.
Amarin is a pharmaceutical company that commercializes VASCEPA (icosapent ethyl), approved in the United States, European Union, and other markets for reducing cardiovascular risk in specific patient populations. The company supplies VASCEPA to distributors globally and operates partnerships with commercial partners across multiple territories including Europe, Canada, Australia, and Asia.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Amarin Corp ADR stock.
Undervalued: intrinsic value $20.80 per share, market price $12.11, margin of safety 41.8% (as of 2026-10-30).
Its liquidation floor, current assets minus every liability, values the shares at $20.80; the price of $12.11 is 42% below that value.
Leak Score: 72/100 on 9 of 12 signals (Clear Leak).
All 21 Drug Manufacturers - General stocks
AMRN is undervalued (as of the 2026-10-30 close). Its liquidation floor, current assets minus every liability, values the shares at $20.80; the price of $12.11 is 42% below that value.
$20.80 per share (as of the 2026-10-30 close), against a market price of $12.11. That is a margin of safety of 41.8%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
72 out of 100, which we rate "Clear Leak", on 9 of 12 value investing signals.